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Exploring the MHC-peptide matrix of central
tolerance in the human thymus
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Ever since it was discovered that central tolerance to self is imposed on developing T cells in
the thymus through their interaction with self-peptide major histocompatibility complexes on
thymic antigen-presenting cells, immunologists have speculated about the nature of these
peptides, particularly in humans. Here, to shed light on the so-far unknown human thymic
peptide repertoire, we analyse peptides eluted from isolated thymic dendritic cells, dendritic
cell-depleted antigen-presenting cells and whole thymus. Bioinformatic analysis of the 842
identiﬁed natural major histocompatibility complex I and II ligands reveals signiﬁcant cross-
talk between major histocompatibility complex-class I and II pathways and differences in
source protein representation between individuals as well as different antigen-presenting
cells. Furthermore, several autoimmune- and tumour-related peptides, from enolase and
vimentin for example, are presented in the healthy thymus. 302 peptides are directly derived
from negatively selecting dendritic cells, thus providing the ﬁrst global view of the peptide
matrix in the human thymus that imposes self-tolerance in vivo.
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A
functional immune system must be able to effectively
recognize and ﬁght pathogens while staying tolerant to
the body’s own components. This is achieved by central
and peripheral tolerance mechanisms. Central tolerance to self is
imposed on T cells during their development in the thymus,
where they are educated to be self-referential, recognizing
peptides bound to self-major histocompatibility complex
(MHC) molecules, as well as self-tolerant, meaning that they
remain unresponsive to self-peptides displayed on the very same
MHC molecules1,2.
In order to fulﬁl both criteria, the ab T cells must pass through
two major checkpoints in their development, which are controlled
by antigen-presenting cells (APCs) in distinct thymic micro-
environments. These APC comprise cortical (cTECs) and
medullary thymic epithelial cells (mTECs), as well as both
resident and immigrant dendritic cells (DCs). During develop-
ment, thymocytes must rearrange their genes in order to express a
functional T-cell receptor (TCR) that can successfully interact
with self-peptide-MHC ligands on cTEC, from which they will
then receive a survival signal (positive selection). Positively
selected thymocytes migrate into the thymic medulla, where they
interact with self-peptide–MHC complexes displayed by mTECs
and DCs. T cells expressing a high afﬁnity TCR for these
complexes will be negatively selected and undergo apoptosis.
Only T cells with a low/intermediate afﬁnity TCR for self-
peptides will be allowed to leave the thymus as naive or regulatory
T cells1,2. If a T cell that strongly recognizes self-peptides fails to
be deleted, for example, because the corresponding self-protein is
not expressed in the thymus or the epitope is destroyed during
antigen processing, autoreactive T cells can escape into the
periphery, where they can be activated and cause autoimmune
disease3. Therefore, the interaction between the TCR of
developing thymocytes and the MHC peptide ligandome of
distinct thymic APCs is crucial for shaping the T-cell repertoire
and central tolerance.
Myeloid DCs (mDCs) in the thymus were the ﬁrst cells
discovered to be responsible for deletion of autoreactive T cells in
the thymus and are crucial for maintaining tolerance to self4,5.
Although, in contrast to mTECs, they are not specialized in
expressing tissue-speciﬁc antigens such as proinsulin, they can
efﬁciently capture these from mTECs and present them to
developing T cells, inducing their deletion, a process that involves
autoimmune regulator expression (AIRE) in mTECs6,7. A role of
plasmacytoid DCs (pDCs) in negative selection has only been
described very recently8 and thymic B cells might also be able to
contribute to negative selection9. Although so far there is no
direct proof that the different subsets of thymic APCs present
different sets of peptides, there are two strong lines of indirect
evidence supporting this notion. First, the different APCs express
different sets of self-proteins. In addition to constitutively
expressed house-keeping proteins and cell-type-speciﬁc
proteins, mTECs express tissue-restricted antigens such as
insulin under the control of the AIRE transcription factor10,11.
Also, blood-born mDCs and pDCs can import peripheral
antigens into the thymus where they delete self-reactive
thymocytes8,12. Second, both the MHC I and II antigen-
processing machinery differs between different thymic APCs,
which should inﬂuence the epitopes that are generated13–16. The
different APCs thus contribute to the diversity of the ‘immunological
self’ displayed in the thymus shaping the characteristics of the
mature T-cell repertoire of each individual.
Our current knowledge regarding the self-peptide repertoire in
the thymus derives mostly from studies in TCR transgenic mouse
models, where expression of a particular antigen is a prerequisite
for positive/negative selection. However, none of these studies
provides evidence that the respective peptides actually contribute
to negative selection under physiological conditions. In the early
nineties, Marrack et al.17 successfully identiﬁed B20 MHC II-
bound peptides in pooled thymi of several hundred mice and a
few natural ligands for positive selection of mouse OT-I cells are
known18,19. More recently, another group has eluted peptides
from whole-mouse thymus, using bioinformatics to narrow down
on likely MHC I ligands20. In humans, presentation of an epitope
from proinsulin on thymic DCs has been reported using
monoclonal antibodies21, but beyond this, the human thymic
peptide repertoire is unknown.
In this work we set out to explore the human thymus MHC
ligandome. We describe an in depth analysis of the peptide
repertoire presented by both MHC class I and class II molecules
in the healthy human thymus, both for whole thymus as well as
isolated thymic mDCs. In summary, we here present the ﬁrst data
on naturally occurring peptides on which human T cells are
selected under physiological conditions, including peptides from
DCs which are responsible for deletion of autoreactive T cells.
Results
Identiﬁcation of peptides presented by thymic APCs. To
address the question which peptides are naturally presented to
developing thymocytes to induce negative selection under phy-
siological conditions in humans, we analysed peptides eluted
from both MHC I (pan-class I human leucocyte antigen; HLA)
and II (HLA–DR) complexes from isolated thymic mDCs by
mass spectrometry and compared them with the repertoire of the
MHC-bound peptides eluted from cells of the APC-enriched,
mDC-depleted (containing pDCs, TECs and other thymic APCs,
that is, ligands for both positive and negative selection) as well as
whole-thymus fractions (Fig. 1).
One major challenge for MS-based analysis of peptides
presented by thymic APCs is their low frequency and their
puriﬁcation in sufﬁcient numbers to allow ligandome analysis.
Typically, the number of cells needed for such experiments is in
the order of 108, limiting the possibilities for analysis of primary
puriﬁed cell types. In our experiments, we identiﬁed a total of 842
peptides from the different cell preparations of the eight
individual thymi investigated, of which 621 were eluted from
MHC I and 221 from MHC II molecules. In the individual mDC
preparations, we successfully identiﬁed up to 90 peptide
sequences eluted from MHC I molecules and up to 48 from
MHC II from as little as 30 106 cells from four different donors
(Table 1). Complete lists of the peptide sequences obtained from
the different samples and their source proteins are given in
Supplementary Data 1.
Cross-talk between MHC I and MHC II pathways. Peptides
presented by MHC I and II derive from different cellular com-
partments. Typically, nuclear and cytosolic proteins are presented
by MHC I, while proteins that are present in the vesicular
compartments or the cell membrane or are taken up from the
extracellular environment are presented by MHC II molecules.
However, especially in professional APCs, there is considerable
cross-talk between those two pathways22. Mechanisms by which
cytosolic/nuclear proteins gain access to the MHC II pathway
include autophagy and uptake of apoptotic cells23,24. Vice versa,
proteins or peptides can shuttle out of the lysosome into the
cytosol and thus gain access to the MHC I pathway22. In addition
to this intracellular cross-talk, DCs may take up antigens from
other cells such as mTECs, further broadening their peptide
repertoire25,26.
To gain insight into the origin of the presented peptides as well
as the dynamics of antigenic cross-talk between MHC presenta-
tion pathways in thymic mDCs and non-mDC APCs, we
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performed automated database analysis supplemented by manual
annotation of the source proteins and their subcellular localiza-
tion. Depending on their topological origin, proteins were
assigned either to the classical MHC class I (cytosolic, nuclear)
or the MHC class II (extracellular, secretory, endocytic, and cell
membrane) pathway, the mitochondrial and the ER compartment
(Fig. 2a). As expected, the majority of MHC I ligands presented
by both DCs and non-DC APCs derived from cytosolic/nuclear
proteins, that normally do not intersect the endocytic compart-
ment, such as histones, cytoskeletal proteins (actin, tubulin and
fascin), metabolic enzymes (protein phosphatase 1, hydroxypyr-
uvate reductase), and cytosolic chaperones (heat shock proteins).
MHC class II-bound peptides originated from proteins present in
different cellular compartments, including the extracellular
milieu, the plasma membrane and the vesicular compartment
with membrane proteins being the most abundant peptide
generators (mostly from MHC class II proteins) in agreement
with previous studies with other cell types24. A substantial
number of MHC II presented peptides originated from blood or
serum proteins, such as serum albumin, haemoglobin and
apolipoprotein A2, providing direct evidence that thymic DCs
sample the blood stream.
Interestingly, a considerable fraction of the MHC II ligands
derived from source proteins localized to the cytosol or nucleus
(35.4% in DCs and 21.8% in non-DCs), which are topologically
separated from the MHC class II pathway. Similarly, 22.4% of
MHC I ligands on DCs derived from the vesicular/extracellular
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Figure 1 | Workﬂow diagram for the isolation of MHC I and MHC II ligands from CD11cþ mDC and the DC depleted, APC-enriched fractions.
Table 1 | MHC I and MHC II ligands identiﬁed on thymic
CD11cþ dendritic cells of individual donors.
Tissue
number
DC cell
number
No. of MHC I
ligands
No. of MHC II
ligands
TT222 36 106 43 47
TT251 66 106 90 35
TT259 33 106 15 19
TT260 30 106 29 24
DC, dendritic cell; MHC I, major histocompatibility complex I; MHC II, major histocompatibility
complex II.
The table contains the number of identiﬁed MHC I- and MHC II-derived peptides, the source
tissue and the number of isolated DCs from which they were eluted.
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compartment (compared with 15.5% in the DC-depleted fraction
and 11.4% in the complete thymus samples). Peripheral DCs are
highly efﬁcient at cross-presenting endocytosed antigens on MHC
I and cytosolic/nuclear antigens on MHC II. It is therefore crucial
to induce central tolerance also to cross-presented self-proteins.
The high degree of cross-talk between the two pathways that we
observe in thymic DCs, as well as to a lesser extent in the
DC-depleted fraction, reﬂects this need to avoid peripheral
autoimmune responses by deleting T cells that recognize
cross-presented self-proteins.
A recent study has underscored the importance of autophagy
for MHC II presentation during central tolerance induction. In
mice, genetic interference with autophagy leads to an altered
selection of certain CD4þ T-cell speciﬁcities that give rise to an
autoreactive T-cell repertoire27. Most of the studies so far have
addressed the in vivo relevance of autophagy mainly in TECs, and
not thymic DCs, but in peripheral DCs autophagosomes have
been shown to fuse with the MHC II loading compartment23. Our
peptide data show considerable presentation of peptides derived
from nuclear/cytosolic as well as some mitochondrial proteins on
MHC class II by thymic mDCs, suggesting a role for autophagy in
MHC II ligands sampling in these cells. Alternatively, these
proteins could enter the MHC II pathway by uptake from other
cells such as apoptotic thymocytes or live/dying mTECs7,28,29 or
transfer of peptide–MHC complexes from mTECs30.
Nature of DC-presented peptides. Analysis of the biological
processes associated with the peptides’ source proteins revealed a
prominent fraction of proteins participating in ‘immune
response’ and ‘antigen processing/presentation’, biological func-
tions reﬂecting the nature of the thymus as an immune organ
(Fig. 2b). The most highly represented class of proteins in these
groups were HLA molecules and, not surprisingly, their
presence was more pronounced in the DC and DC-depleted
samples (enriched for other thymic APCs), compared with
whole-thymus samples. Most of the remaining class I and II
natural ligands derive from house-keeping proteins (signalling,
100%
a
b
90% 29
209 105 118 40 17
33 23 69 57
Unknown
Mitochondrial
MHC II
MHC I
ER
80%
70%
60%
50%
40%
30%
20%
10%
0%
100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%
Whole-
thymus
MHC I
CD11c+ 
DC
MHC I
DC-
depleted
MHC I
CD11c+ 
DC
MHC II
DC-
depleted
MHC II
Whole-
thymus
MHC I
CD11c+
DC
MHC I
DC-
depleted
MHC I
CD11c+
DC
MHC II
DC-
depleted
MHC II
Cell death
Cellular component organization
Other/unknown
Translation
Response to stress
Cell differentiation and development
Cell cycle, growth and proliferation
Metabolic process
Transport
Viral reproduction
Signalling
Antigen processing and presentation
Immune response
Figure 2 | MHC pathway assignment and functional categorization of the identiﬁed source proteins isolated from the different thymic sample
preparations. The cellular localization (a) and biological processes (b) of the protein categories represented graphically as percentages are based on
n¼ the number of the individual proteins identiﬁed in each thymic APC preparation.
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms3039
4 NATURE COMMUNICATIONS | 4:2039 |DOI: 10.1038/ncomms3039 | www.nature.com/naturecommunications
& 2013 Macmillan Publishers Limited. All rights reserved.
translation, metabolism, cell cycle and proliferation). Interest-
ingly, peptides derived from proteins associated with metabolic
processes are preferentially presented on MHC class II molecules,
and peptides derived from proteins involved in cell cycle, growth,
proliferation and differentiation are more abundantly presented
on MHC class I molecules. The explanation for the preferential
presentation of peptides derived from proteins involved in these
processes by MHC I is that in these groups the majority of
peptides derive from nuclear and cytosolic proteins involved in
maintaining cellular structure (for example, the cytoskeleton) and
transcription. These are typically degraded by the proteasome and
presented via the classical MHC I pathway22. A closer look at the
metabolic processes-associated proteins revealed that many of the
MHC II-bound identiﬁed peptides in this group derived from
cytosolic proteins. The sources of these peptides included a
considerable number of long-lived constitutive metabolic
enzymes like glyceraldehyde 3-phosphate dehydrogenase and
phosphoglycerate kinase 1. Interestingly, long-lived proteins have
been suggested to be disposed by autophagic rather than
proteasomal protein degradation31. Autophagic degradation of
cellular material has been shown to signiﬁcantly contribute to the
peptide pool presented by MHC II (refs 23,24). In agreement with
our results and in support of this idea, glyceraldehyde 3-phosphate
dehydrogenase was previously identiﬁed as a source of natural
MHC class II, but not class I ligands24,32. Hence, autophagic
degradation of long-lived metabolic proteins might explain why
these cytosolic proteins are presented by MHC class II rather than
class I. The observed wide cellular functional distribution of
proteins reﬂects the wide range of proteins that serve as a matrix
for self-protein presentation in the thymus.
Peptides differ between individuals and APC. It has been sug-
gested that different types of thymic APC present different non-
overlapping set of self-proteins, despite the existence of pathways
allowing protein/peptide transfer between cells and despite the
fact that a lot of basic cellular components like metabolic
enzymes, and structural proteins should be expressed at similar
levels in most cells. One reason for this might be the differences
in the antigen-processing machinery between the different cell
types13–16. To address this question, we compared the source
proteins of peptides presented on DCs to that of the DC-depleted
fraction (enriched for other thymic APCs, for composition see
Supplementary Table S1 and Supplementary Fig. S1). In total, we
identiﬁed 302 peptides originating from 187 different proteins on
DCs and 265 peptides from 184 different proteins in the DC-
depleted fraction, 71 of which were present in both fractions
(Fig. 3a). These include proteins such as HLA molecules, histones,
proliferating cell nuclear antigen, actin, pyruvate kinase, serum
albumin and b2 microglobulin. Although, B1/3 of the protein
pool was shared between DCs and non-DC cells, the majority of
the identiﬁed proteins were unique for each group, supporting the
idea that different thymic APCs present different peptides.
Data from whole thymus indicated a large degree of variability
of the source proteins from which peptides were presented in
different donors (Supplementary Fig. S2), probably partially due
to differences in HLA-binding preferences and protein expres-
sion. Quantitative differences in expression levels of individual
MHC–peptide complexes might also play a role as our
experimental approach preferentially detects high abundance
peptides, especially when source material is limiting. To exclude
the possibility that the limited overlap observed was due to issues
of technical reproducibility rather than bona ﬁde biological
variability, we performed extensive validation experiments which
showed that technical reproducibility was in the order of 85%,
while the overlap between samples derived from different donors
was much lower (Supplementary Fig. S3), demonstrating that the
differences observed were indeed due to biological, and not
technical, variability.
To clarify whether this variability was also observed for the
self-proteins directly involved in negative selection of T cells, we
compared the source proteins of the peptides eluted from thymic
DCs from different donors (Fig. 3b). Of the 187 proteins whose
peptides were presented by mDCs, only 27 were detected in more
than one donor, and only one (HLA-DRB1) was shared by the
four individual thymic DC samples. Peptides from seven proteins
(HLA-DRA, serum albumin, tubulin b 2A chain, serine/
threonine-protein phosphatase PP1, astrocytic phosphoprotein
PEA-15, bax inhibitor 1, signal transducer and activator of
transcription 1-a/b) could be detected in three out of four DC
samples, but peptides from the vast majority of proteins (160)
were only detected in one sample, reﬂecting a high inter-
individual variability in the peptide matrix for negative selection.
A similar picture is observed in the DC-depleted-derived peptide
pool (Fig. 3c).
To further explore the differences between the HLA ligandome
of DCs and non-DCs, we directly compared the source proteins
(Fig. 4a) and the protein-derived peptides (Fig. 4b) that are
present on the respective fractions from the same donors,
eliminating the contribution of HLA-binding preference to
peptide variability between fractions. Interestingly, only about a
ﬁfth of the detected proteins were presented by both DC and non-
DC APCs, and for donor TT259 the overlap was even smaller. In
summary, we demonstrate a high inter-individual variability of
the MHC ligandome and furthermore, our results agree with the
notion that different, but overlapping spectra of self-proteins on
different thymic APCs results in partially non-redundant
contributions of different APCs to negative selection.
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Figure 3 | Inter-individual variation in presentation of peptides from different source proteins presented by MHC I and II. The diagrams depict the
number of different source proteins identiﬁed in the different cell preparations as well as overlap between samples. (a) Overlap of identiﬁed proteins
between mDC and mDC-depleted (enriched for other APC) fractions (individual donors taken together). Inter-individual variations of proteins presented on
(b) DC of four different donors and (c) DC-depleted fractions of three individuals, respectively.
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T-cell epitopes linked to autoimmunity. Incomplete repre-
sentation of the full spectrum of self-proteins (the ‘immunological
self’) on MHC molecules of mTECs and DCs will result in a lack
of central tolerance to those epitopes that are not displayed,
increasing the propensity for autoreactivity among mature T cells
in the periphery1,33.
We were therefore particularly interested whether we could
identify peptides corresponding to known T-cell epitopes that
have been described as targets in human autoimmune diseases.
Literature search yielded a number of T-cell autoantigens that
were also detectable in our samples (Table 2). The table only
includes T-cell autoantigens for which reactivity has been
experimentally veriﬁed in humans, such as vimentin (rheumatoid
arthritis, sarcoidosis)34,35, ATP synthase (sarcoidosis)35, enolase 2
(multiple sclerosis)36 and heat shock protein 70 (type 1 diabetes
mellitus)37. For those autoantigens where reactivity against
speciﬁc epitopes (rather than whole protein) was reported, the
epitopes were identical to, or contained within the peptide
sequences that we identiﬁed in our samples, mostly on DCs. This
clearly demonstrates presentation of these epitopes in normal
human thymus, which should lead to deletion of autoreactive
T cells. We therefore hypothesize that in patients with autoimmune
disease, presentation of these epitopes could be impaired,
resulting in failure of central tolerance towards these epitopes.
Tumour-associated antigens in the thymus. Central tolerance is
a double-edged sword. Although it protects us from autoimmune
disease, it can also impede anti-tumour immunity. It is likely that
presentation of self-proteins which tolerize the T-cell repertoire to
self-antigens in order to avoid autoimmunity may also negatively
impact the ability of T cells to mediate tumour immunity. This
prediction has been conﬁrmed by studies demonstrating the
expression of tumour-associated antigens, including differentia-
tion antigens and cancer-germline antigens, in human mTECs38,
and moreover, expression of the human carcinoembryonic
antigen (CEA), in mTECs of transgenic mice induces central
tolerance39. A thorough literature search on natural MHC ligand
repertoires in tumours revealed that a signiﬁcant number of the
MHC-bound peptides detected in our experiments are also found
to be (over)presented in renal cell carcinomas40,41 or other
disease tissues (Supplementary Data 2), including the SET nuclear
oncogene and APOL1. Our ﬁndings provide an explanation why
only low-avidity T cells against many cancer-associated antigens
are present in the periphery42, as presentation of tumour-
associated antigens by negatively selecting cells of the thymus
should result in the deletion of high-avidity T cells. Therefore,
even if they are found to be overexpressed on tumour tissues, they
might not be the ﬁrst choice as a target for immunotherapy. An
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Table 2 | T-cell autoantigens/epitopes in humans identiﬁed in different thymus samples.
Autoantigen Epitope (thymus) Thymus fraction Disease Epitope used in T-cell assay Assay type Ref.
Vimentin RETNLDSLPL (424–433) DC Rheumatoid arthritis LPNFSSLNLRETNLDSLPL (415-433) ICS
IFN-g
34
Hþ/Kþ ATPase
(ATP synthase)
VPPVQVSPLIKLG
RYSAL (2–19)
DC depleted Sarcoidosis VPPVQVSPLIKLGRYSAL (2–19) ELISPOT
IFN-g
51
b-actin RVAPEEHPVL (95–104) DC Sarcoidosis NELRVAPEEHPVLLT (92–106) ELISPOT
IFN-g
51
Heat shock protein 70 NVLRIINEP
TAAAIA(168–182)
DC
DC depleted
Type 1 diabetes mellitus GLNVLRIINEPTAAAIAYGL (166–185)
3H-thymidine 37
Enolase 2 IVGDDLTVTNPK DC Multiple sclerosis Whole protein 3H-thymidine 36
Cytokeratin 17 RLASYLDKV (125–133) Whole thymus Psoriasis RLASYLDKV (125–133) ICS
IFN-g
52
DC, dendritic cell; ICS, intracellular cytokine staining; IFN-g, interferon-g.
The table shows the autoantigens and the derived peptides identiﬁed in our samples as well as the preparation in which we could identify them, the autoimmune disease in which T-cell responses against
the autoantigen/epitope have been experimentally veriﬁed, the epitope (where available) as well as the experimental method by which T-cell responses were measured in the respective publication.
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example is p53, a tumour suppressor with a central role in
tumour development. Here, we detected a p53-derived peptide
presented on MHC I on DCs (Supplementary Data 1 and 2),
which should lead to thymic deletion of p53-speciﬁc CD8þ T
cells. This is in line with a recent ovarian cancer study describing
the lack of spontaneous p53-speciﬁc CD8þ , but not CD4þ -
speciﬁc T-cell responses in healthy donors and patients with high
antibody titres against p53 (ref. 43).
Discussion
In summary, we provide here the ﬁrst characterization of the
peptide repertoire presented by MHC molecules in the healthy
human thymus in vivo with a focus on those epitopes presented
by mDCs that are important for negative selection. Interestingly,
both known autoantigens as well as tumour-associated antigens
were detected. We observed a high degree of inter-individual
variability between donors that can in part be explained by
differences in HLA type but might also be partially due to
differences in protein expression. Furthermore, mDCs and non-
mDC APCs present different, only partially overlapping sets of
peptides, probably due to differences both in self-protein
expression as well as differences in their antigen-processing
machinery13,15.
Although our data contribute to answer the long-standing
question of which peptides are physiologically involved in T-cell
selection in the human thymus, many issues still remain to be
addressed before we fully understand the process of central
tolerance. For example, analysis of ligands derived from isolated
mTECs or cTECs as well as low abundance ligands presented by
DCs is currently limited by available technology. For this reason,
the data presented here are from mDCs only, and do not include
ligands from isolated mTECs, which also contribute to central
tolerance. Another question that remains to be addressed is
whether the thymic ligandome changes considerably during the
lifetime of an individual. For obvious reasons it will be difﬁcult to
answer this question experimentally in humans, but some
previous studies suggest that variation is likely to occur. Thymic
DCs and mTECs have a half-life of about 2–3 weeks and at least
for mTECs, considerable differences in tissue-restricted antigen
expression between different cells have been described44. Our and
other data support the idea that thymic DCs sample the blood
stream for proteins, and peripheral DCs can take up antigens,
migrate to the thymus and delete the corresponding T cells8,12.
Changes in the periphery would therefore be expected to impact
on the peptides presented in the thymus.
Our data should pave the way for a comprehensive under-
standing of central tolerance and might one day help to improve
the design of therapeutic interventions such as cancer vaccines.
The expression of ligands derived from tumour-associated
antigens on thymic APCs highlights the need for a more
systematic analysis of potential cancer vaccine candidates,
employing our data to preselect or exclude antigens from the
growing list of candidates in future vaccine trials.
Methods
Thymic samples. Normal human thymus samples were obtained from children
undergoing corrective cardiac surgery (Department of Cardiac Surgery, University
of Tu¨bingen, Germany) after parents’ informed consent and approval by the
Institutional Review Board of the Medical Faculty of the University of Tu¨bingen.
For details of donors see Table 3.
Genotyping of thymic tissues. DNA for HLA genotyping was extracted from
thymus tissue using the QIAamp DNA Blood Mini kit (Qiagen). Low-resolution
HLA typing was performed by the Institute for Clinical and Experimental
Transfusion Medicine (IKET), University of Tu¨bingen, Germany.
Isolation of thymic DCs. mDCs were isolated from thymus tissue after mechanical
and enzymatic disruption (collagenase (1mgml 1) and DNase (50 mgml 1, both
from Roche), at 37 C, two to three times for 30–45min)14. APCs were enriched
from the resulting single-cell suspension by Percoll gradient centrifugation
(density: 1.07 gml 1, 30min, 3,500 g, 4 C) and DCs were isolated by magnetic
beads (CD11c-PE and anti-PE beads, Miltenyi Biotec) from the low-density
fraction following the manufacturer’s instructions. Both the positive (DC) and
negative (DC-depleted) fractions (for composition see Supplementary Table S1
and Supplementary Fig. S1) were collected. A summary of the workﬂow is
given in Fig. 1.
FACS Analysis. Single-cell suspensions from whole thymus, the APC-enriched
fraction after Percoll, DC and DC-depleted fractions were stained with antibodies
against HLA–DR (PerCP, 307628, 1:50), CD19 (FITC, 302205, 1:20), CD14 (APC,
301807, 1:50), CD45RA (FITC, 304105, 1:10), CD123 (PE/Cy7, 306009, 1:10), (all
from Biolegend), CD45 (PB, PB986, 1:10, DAKO), BDCA-4 (PE, 130-090-533,
1:10), CD11c (PE, 130-092-411, 1:10), EpCAM (APC, 130-091-254, 1:10, from
Miltenyi Biotec), CDR2 (1:50, Bruno Kyewski, DKFZ, Heidelberg; labelled with
Alexa488 using the Alexa Fluor 488 Protein Labelling kit from Molecular Probes
according to manufacturer’s instructions). mDCs were gated as CD11cþ , B cells
were gated as CD19þ , pDCs as CD45RAþBDCA-4þ , monocytes as CD14þ ,
mTEC and cTEC as CD45lo-negEpCAMhi or CD45lo-negEpCAMloCDR2þ ,
respectively.
Elution of MHC ligands. MHC-bound peptides were isolated using antibodies
L234 (HLA–DR) and W6/32 (pan-HLA class I)45,46. We have also published a
detailed step-by-step protocol of this procedure45. Frozen-cell pellets or tissue
pieces were lysed with 0.6% CHAPS with protease inhibitors in PBS, stirring for 2 h
at 4 C. The resulting lysate was ultrasonicated, and debris pelleted by
centrifugation (4,000 g for 20min, followed by ultracentrifugation at 40,000 r.p.m.
for 1 h). The supernatant was clariﬁed by ultraﬁltration (0.2 mm pore size, Sartolab
P plus, Sartorius) and peptide–MHC complexes were isolated from the supernatant
by afﬁnity chromatography (antibodies L234 (MHC II) or W6/32 (MHC I)
coupled to CNBr-Sepharose, overnight, 4 C). Bound MHC–peptide complexes
were eluted with 0.1% TFA. Eluted peptides were separated from MHC proteins by
centrifugation though a ﬁlter with a MW cutoff of 10 kDa and analysed by
LC-MS/MS.
Identiﬁcation of MHC ligands. Nanoscale liquid chromatography of MHC
ligands was performed with a Waters NanoAcquity UPLC system equipped with a
75 mm 150mm BEH C18 reversed phase column and a 2.6-ml PEEKSIL-sample
loop (SGE, Darmstadt, Germany). The aqueous mobile phase (mobile phase A) was
H2O with 0.1% formic acid. The organic mobile phase (mobile phase B) was 0.1%
Table 3 | Age, gender and HLA typing of thymus tissue
donors included in this study.
Tissue no. Age Gender HLA typing
TT208 15 years F A*01, A*33, B*49:01, B*51,C*07, C*16
DRB1*11, DRB1*13, DRB3
TT222 6 months F A*01, A*24, B*40, B*44
DRB1*04, DRB1*12, DRB3, DRB4
TT233 6 years F A*02, B*78, C*16
DRB1*13 DRB3
TT246 2 years M A*02, A*25, B*13, B*18, C*06, C*12
DRB1*07:01, DRB1*15:01
TT247 2 years M A*01, A*30, B*08, B*27
DRB1*03:01, DRB1*15:01
TT251 8 months M A*26, A*66, B*35, B*38, C*04, C*12
DRB1*03, DRB1*11, DRB3
TT259 5 years M A*02, A*24, B*13, B*27, C*01, C*06
DRB1*0103, DRB1*15, DRB5
TT260 11 months F A*24, A*26, B*18, B*55, C*02, C*03
DRB1*11, DRB3
F, female; HLA, human leucocyte antigen; M, male.
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms3039 ARTICLE
NATURE COMMUNICATIONS | 4:2039 | DOI: 10.1038/ncomms3039 |www.nature.com/naturecommunications 7
& 2013 Macmillan Publishers Limited. All rights reserved.
formic acid in acetonitrile. Samples (2.6 ml injection) were loaded onto the column
in direct injection mode with 3% mobile phase B for 15min at 400 nlmin 1,
followed by an additional 10min wash (3% B) for 10min at 300 nlmin 1. Peptides
were eluted from the column with a gradient from 3–35% mobile phase B over
120min at 300 nlmin 1 followed by a 20-min rinse of 80% mobile phase B. The
column was immediately re-equilibrated at initial conditions (3% mobile phase B)
for 20min. [Glu1] ﬁbrinopeptide was used as lockmass at 500 fmol ml 1. Lockmass
solution was delivered from the auxiliary pump of the NanoAcquity system at
400 nlmin 1 to the reference sprayer of the NanoLockSpray source. MS/MS
analysis of peptides was performed by using a Waters Q-Tof Premier mass spec-
trometer operated in V-mode with typical resolving power of R¼ 10.000 in data-
dependent acquisition mode, selecting the three most intense precursor ions for
fractionation in the collision cell. Fragmentation of the parent ions was achieved by
collision with argon atoms. Collision energy was varied from 15–35 eV dependent
on precursor ion mass and charge. The integration time for the TOF analyser was
1 s with an interscan delay of 0.1 s.
Interpretation of MS/MS fragmentation spectra was carried out manually using
MassLynx 4.0 software47. For manual peptide identiﬁcation, sequence tag searches
were done using Mascot 2.0 software (peptide and MS/MS tolerance, 0.2Da;
National Center for Biotechnology Information non-redundant (NCBInr) database
updated monthly and restricted for search to human entries), and relevant hits
were assessed manually and not by evaluation of the Mascot score. Criteria for
manual identiﬁcation were: a reasonable interpretation of at least 95% of all
fragment peaks, complete sequence coverage with MS/MS fragments, and signal
intensities of fragment ion peaks that match breakage probabilities of the respective
sequence.
The obtained peptide sequences were assigned to source proteins using the
BLAST algorithm and further bioinformatics analysis48,49 was performed. The
MHC class I and MHC class II ligands in different thymic cell preparations were
assigned to subcellular compartments or functional categories according to Gene
Ontology annotations (www.geneontology.org). In cases where this search yielded
no or incomplete information, annotation was performed manually based
on information from WoLF PSORT48 (wolfpsort.org), SubLoc49
(www.bioinfo.tsinghua.edu.cn/SubLoc/), SwissProt and published literature. Source
proteins were then grouped to the classical MHC I (cytosolic, nuclear) or MHC II
pathway (extracellular, vesicular and cell membrane), the mitochondrial or ER
compartment. To facilitate interpretation of data for biological function, related
subcategories were grouped together, for example, ‘signalling’, ‘cell–cell signalling’
and ‘signal transduction’ were grouped together as ‘signalling’. All peptides were
assigned to a speciﬁc HLA allotype by taking the HLA type of the patient into
consideration as well as known binding motifs of different allotypes50. Peptides
were assigned to the presenting HLA molecule by comparison of their anchor
amino acids with known HLA allele-speciﬁc peptide motifs. In order to carry out
an automated, reproducible assignment to the correct HLA allotype, all peptide
sequences were subjected to epitope prediction using the database SYFPEITHI
(ref. 50) (www.syfpeithi.de), evaluating the preferential binding to one of the HLA
allotypes deﬁned by HLA typing. SYFPEITHI calculates scores according to the
preferred amino acids in each sequence position. Peptides receiving more than the
half-maximal score for a given HLA molecule were assigned to the respective
molecule. It has to be noted that ligands of different HLA molecules may achieve
different maximal scores. The maximal scores are 44 for HLA-A*03, 44 for
HLA-A*26, 29 for HLA-A*31, 37 for HLA-A*32, 33 for HLA-B*07, 30 for
HLA-B*38 and 38 for HLA-B*51. If epitope prediction was not possible by the web
version of SYFPEITHI, an in-house version with extended options was used. This
was the case for predictions of HLA-A*31 and HLA-A*32 ligands and for rarely
occurring peptide lengths (8 mer, 11 mer) of other HLA allotypes.
Reproducibility analysis. For method validation and reproducibility analysis,
MHC I peptides from PBMC of healthy volunteers were isolated and technical
replicates performed. For statistical analysis of the intra-sample (that is, technical)
reproducibility, the overlaps of every conceivable pair of technical replicates were
calculated for one randomly selected sample. For the assessment of inter-individual
variability we analysed the overlaps of HLA ligand source proteomes of ﬁve healthy
volunteer PBMC samples. We performed comprehensive overlap analysis of all ﬁve
samples. For the statistical analysis of inter-individual variability, paired overlap
analyses of all 10 possible combinations of source proteomes were performed. The
two populations (technical replicate overlaps versus inter-individual overlaps) were
compared using a two-sided, unpaired Student’s t-test not assuming equal standard
deviations (Supplementary Fig. S3).
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